Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 8/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 8/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6049689 | 1.00 | HDAC1 (0.55) | HDAC1HDAC2HDAC3HDAC4HDAC7 | |
| SCHEMBL6159560 | 0.89 | KCNA3 (0.55) | HDAC1HDAC2ITGB3ITGA2BLTA4H | |
| SCHEMBL6161530 | 0.89 | KCNA3 (0.55) | HDAC1HDAC2ITGB3ITGA2BLTA4H | |
| Bromide SCHEMBL6049715 | 0.88 | LTA4H (0.56) | HDAC1HDAC2PPARGPPARAITGB3 | |
| Bromide SCHEMBL6049719 | 0.88 | LTA4H (0.56) | HDAC1HDAC2PPARGPPARAITGB3 | |
| Bromide SCHEMBL6049682 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BLTA4HFFAR1 | |
| Bromide SCHEMBL6049677 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BLTA4HFFAR1 | |
| Bromide SCHEMBL6049795 | 0.85 | ITGB3 (0.58) | ITGB3ITGA2BLTA4HFFAR1 | |
| Bromide SCHEMBL6049776 | 0.85 | ITGB3 (0.58) | ITGB3ITGA2BLTA4HFFAR1 | |
| Bromide SCHEMBL6049794 | 0.85 | ITGB3 (0.58) | ITGB3ITGA2BLTA4HFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878723-B1 | Carbocyclic and/or heterocyclic amino carboxylic acids, e.g., 2-aminomethyl-6-(p-benzylphenoxy)hexanoic acid; leukotriene A4 hydrolase; treating arthritis and psoriasis; hematoprotective and antimitotic agents | INSTITUT NATIONAL DE LA SANTE ET DE LA RESCHERCHE MEDICALE (INSERM) (FR) | 2005-04-12 | — | — | US | claimed |
| US-7094773-B2 | LTA4 hydrolase inhibitors | Institut National de la Santa et de la rescherche Medicale Bioprojet (FR) | 2006-08-22 | — | — | US | disclosed |
| US-6878723-B1 | Carbocyclic and/or heterocyclic amino carboxylic acids, e.g., 2-aminomethyl-6-(p-benzylphenoxy)hexanoic acid; leukotriene A4 hydrolase; treating arthritis and psoriasis; hematoprotective and antimitotic agents | INSTITUT NATIONAL DE LA SANTE ET DE LA RESCHERCHE MEDICALE (INSERM) (FR) | 2005-04-12 | — | — | US | disclosed |
| US-20050027013-A1 | LTA4 hydrolase inhibitors | DANVY DENIS (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027013-A1 | LTA4 hydrolase inhibitors | LTA4H, LTC4S, LTB4R | HDAC1 2381/4885HDAC2 2269/4885HDAC3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.